AlzChem Group (ACT) Q1 2025 earnings summary

Executive summary

• Q1 2025 delivered strong performance with EBITDA up 10% to EUR 27.4 million and margin rising to 18.9%, driven by growth in Specialty Chemicals despite a 4% sales decline to EUR 144.7 million.

• Free cash flow increased to EUR 36.4 million, supported by significant customer prepayments for nitroguanidine capacity expansion.

• Major investment projects, including nitroguanidine expansion, are on schedule, with initial customer contributions received and US site selection underway.

• 2025 outlook confirmed for record sales and EBITDA, with no material impact from US tariff changes in Q1.

• Global Creatine Conference hosted, reinforcing leadership in the creatine market.

Financial highlights

• Q1 2025 sales were EUR 144.7 million, down 4% year-over-year; EBITDA rose 10% to EUR 27.4 million, with margin at 18.9%.

• Net income increased 20% to EUR 14.6 million; EPS rose to EUR 1.44.

• Operating cash flow reached EUR 49.5 million, up 48% year-over-year; free cash flow up 37% to EUR 36.4 million.

• Equity ratio at 40% as of March 31, 2025, with equity up by EUR 15 million.

• Cash and cash equivalents rose 48.5% to EUR 91.4 million.

Outlook and guidance

• Full-year 2025 sales expected at approximately EUR 580 million and EBITDA at EUR 113 million, driven by higher volumes in specialty chemicals.

• Slight decline expected in Basics & Intermediates; no material negative impact from US tariff changes.

• Assumptions include stable global economy, high electricity prices, and no major geopolitical disruptions.